Notice of Effectiveness · EFFECT
NewcelX Ltd.
NCELNASDAQEQUITYCurrent
Notice of Effectiveness
Structured filing — EFFECT
primary_doc.xml
Notice details
- Submission type
- EFFECT
- Act
- 33
Effectiveness
- Effective date
- 2026-09-22
- Submission type
- POS AM
- Related accession
- 0001213900-26-101429
Registrant 1
- Registrant
- NewcelX Ltd.
- Registrant CIK
- 0001783036
- File number
- 333-290516
Company context
NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the Company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.